{"title":"Augmented mannose-binding lectin levels in primary membranous nephropathy: A pilot study.","authors":"Deeksha Pal, Neeraj Inamdar, Prabhjot Kaur, Manphool Singhal, Anupam Lal, Ujjwal Gorsi, Ritambhra Nada, Harbir S Kohli, Vinod Kumar, Raja Ramachandran","doi":"10.1111/nep.14293","DOIUrl":"10.1111/nep.14293","url":null,"abstract":"<p><p>There is evidence to suggest that M-type phospholipase A2 (PLA2R) antibodies activate the mannose-binding lectin (MBL) cascade, resulting in glomerular damage and proteinuria in patients with primary membranous nephropathy (PMN). Furthermore, there are few reports indicating that aberrant MBL activation is associated with endothelial dysfunction and accelerated atherosclerosis. While PMN is a common cause of adult nephrotic syndrome, and patients are at increased risk of cardiovascular disease (CVD), there is a lack of research that explores the factors that contribute to this condition. This study aims to determine the MBL levels in PMN and their relation to the clinical activity and endothelial dysfunction in PMN. The MBL levels of 22 biopsy-confirmed PMN patients were assessed at baseline and after 6 months of immunosuppressive therapy. In order to evaluate endothelial dysfunction in PMN patients, flow-mediated vasodilation (FMD) was measured at baseline and after treatment. A total of 22 healthy controls were included in this study to measure MBL levels and FMD. A significant difference was observed between MBL levels in PMN patients and healthy controls (p < .01). MBL levels decreased significantly after immunosuppressive therapy (p = .04). The baseline MBL levels and FMD levels exhibited a strong correlation (Spearman correlation coefficient [ρ] = 0.51: p = .01). In conclusion, the study signals the activation of the MBL cascade and its association with endothelial dysfunction in PMN patients.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"617-621"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01Epub Date: 2024-05-08DOI: 10.1111/nep.14313
Meng Yang, Le Wang, Xiong-Fei Sun, Dong-Qi Yin
{"title":"Renal thrombotic microangiopathy is associated with poor renal survival in children with immunoglobulin A nephropathy.","authors":"Meng Yang, Le Wang, Xiong-Fei Sun, Dong-Qi Yin","doi":"10.1111/nep.14313","DOIUrl":"10.1111/nep.14313","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to examine the clinical and pathological characteristics as well as the prognosis of immunoglobulin A nephropathy (IgAN) accompanied by renal thrombotic microangiopathy (rTMA) in paediatric patients.</p><p><strong>Methods: </strong>After balancing epidemiological characteristics and pathological types between groups, 427 patients (rTMA group: 23, non-rTMA group: 46) were included. The clinical and pathological features, prognosis and clinical risk factors of the two groups were analysed.</p><p><strong>Results: </strong>IgAN-rTMA children showed more severe clinical and pathological manifestations. The findings from the logistic regression analysis indicated that hypercellularity 1 (E1) (HR: 0.805, 95% CI: 0.763 ~ 1.452, P = .016), endocapillary proliferation (HR: 1.214, 95% CI: 0.093 ~ 4.815, P = .025) and C3 staining (HR: 7.554, 95% CI: 2.563 ~ 15.729, P = .037) were the risk factors for rTMA in children with IgAN. The renal survival in rTMA group was lower than non-rTMA group (χ<sup>2</sup> = 18.467, P = .000). Cox regression analysis showed that E1 (HR: 7.441, 95% CI: 1.095 ~ 10.768, P = .037), C3 disposition (HR: 3.414, 95% CI: 0.834 ~ 11.578, P = .027) and rTMA (HR: 8.918, 95% CI: 1.032 ~ 16.754, P = .041) were identified as independent risk factors for the development of end-stage renal disease (ESRD).</p><p><strong>Conclusion: </strong>The presence of rTMA had a significant impact on the severity and prognosis of IgAN. And rTMA has been identified as an independent risk factor for the development of renal failure in children diagnosed with IgAN.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"579-587"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01DOI: 10.1111/nep.14374
{"title":"17th International Symposium on IgA Nephropathy (IIgANN), 28-30 September, Tokyo.","authors":"","doi":"10.1111/nep.14374","DOIUrl":"https://doi.org/10.1111/nep.14374","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"4"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01Epub Date: 2024-07-03DOI: 10.1111/nep.14340
Yuemiao Zhang, Hong Zhang
{"title":"Current understanding and new insights in the treatment of IgA nephropathy.","authors":"Yuemiao Zhang, Hong Zhang","doi":"10.1111/nep.14340","DOIUrl":"10.1111/nep.14340","url":null,"abstract":"<p><p>IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, and almost all patients are at risk of progression to end-stage kidney disease within their lifetime. The mechanisms responsible for the presentation and development of IgAN are required for the development of highly targeted therapies for this disease. In this review, we first demonstrate the current treatment strategy of IgAN recommended by the 2021 KDIGO guideline. Then, we update the new insights into disease pathogenesis based on the well acknowledged 'multiple-hit hypothesis' and provide the potential therapeutic targets involved in the upstream production of pathogenic IgA1 and the downstream complement activation. Finally, the recent large randomized controlled trials focusing on these novel targets have been summarized, among which Nefecon and Sparsentan have received approval and Telitacicept have been used off-label for IgAN. In the future, emerging treatment approaches for IgAN is likely to evolve, which will signify a shift in the management of the IgAN from traditional immunosuppressive approaches to an era of targeted treatment based on the understanding of the pathogenic mechanisms.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"75-79"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141492792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01Epub Date: 2024-07-16DOI: 10.1111/nep.14339
Heather N Reich, Yuko Makita
{"title":"The pathogenesis of IgAN: Where is pathogenic IgA produced?","authors":"Heather N Reich, Yuko Makita","doi":"10.1111/nep.14339","DOIUrl":"10.1111/nep.14339","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"68-70"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01DOI: 10.1111/nep.14345
Suceena Alexander
{"title":"Post-conference review of oral session 6 and short talk in the 17th international IgA nephropathy conference, Tokyo 2023.","authors":"Suceena Alexander","doi":"10.1111/nep.14345","DOIUrl":"10.1111/nep.14345","url":null,"abstract":"<p><p>Oral session 6 titled 'Clinical Trial 1' and the short talk on 'Landscape of Clinical Trials in IgAN-What's beyond the Horizon?' took place on 30 September 2023 in the symposium venue. The short talk highlighted the increase in IgAN trials in the last decade and the challenges of global clinical trials from the site investigator perspective. The talk also underlined the importance of relooking and repurposing already available and approved therapeutics. There were six oral sessions that focussed mainly on the interim results of ongoing clinical trials as well as early phase results with new investigational agents.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"63-64"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01DOI: 10.1111/nep.14344
Renato C Monteiro
{"title":"Closing remarks from the IIGANN2023 Tokyo symposium-40 years of study progress in IgA nephropathy.","authors":"Renato C Monteiro","doi":"10.1111/nep.14344","DOIUrl":"https://doi.org/10.1111/nep.14344","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"80-83"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01DOI: 10.1111/nep.14341
Bruce A Julian
{"title":"My lifetime in IgA nephropathy: An unexpected journey.","authors":"Bruce A Julian","doi":"10.1111/nep.14341","DOIUrl":"10.1111/nep.14341","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"55-59"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NephrologyPub Date : 2024-09-01DOI: 10.1111/nep.14349
Sean J Barbour
{"title":"The epidemiology of IgA nephropathy: East versus West.","authors":"Sean J Barbour","doi":"10.1111/nep.14349","DOIUrl":"10.1111/nep.14349","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"65-67"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}